References for:
Stress-Dose Corticosteroid Therapy for Sepsis and Acute Lung Injury or Acute Respiratory Distress Syndrome in Critically Ill Adults

[Pharmacotherapy 22(9):1140-1156, 2002. © 2002 Pharmacotherapy Publications]

  1. American College of Chest Physicians-Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
  2. Angus DC, Linde-Zwirble WT, Lidisker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
  3. Rangel-Frausta MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995;273:117-23.
  4. Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia: United States, 1979-1987. JAMA 1990;263:937-8.
  5. Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers: academic medical center consortium sepsis project working group. JAMA 1997;278:234-40.
  6. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001;29:S109-16.
  7. Bernard GR, Artigas A, Brigham KL, et al. The American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Resp Crit Care Med 1994;149:818-24.
  8. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-49.
  9. Meduri GU. The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. Eur Respir J 1996;9:2650-70.
  10. Pola MD, Navarrete-Navarro P, Rivera R, Fernandez-Mondejar E, Hurtado B, Vazquez-Mata G. Acute respiratory distress syndrome: resource use and outcomes in 1985 and 1995, trends in mortality and comorbidities. J Crit Care 2000;15:91-6.
  11. Headley AS, Tolley E, Meduri GU. Infections and the inflammatory response in acute respiratory distress syndrome. Chest 1997;111:1306-21.
  12. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001;29:S99-106.
  13. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207-13.
  14. Fein AM, Calalang-Colussi MG. Acute lung injury and acute respiratory distress syndrome in sepsis and septic shock. Crit Care Clin 2000;16:289-317.
  15. Ihle BU. Adrenocortical response and cortisone replacement in systemic inflammatory response syndrome. Anaesth Intensive Care 2001;29:155-62.
  16. Spijkstra JJ, Girbes ARJ. The continuing story of corticosteroids in the treatment of septic shock. Intensive Care Med 2000;26:496-500.
  17. Annane D. Corticosteroids for septic shock. Crit Care Med 2001;29:S117-20.
  18. Lamberts SWJ, Bruining HA, De Jong FH. Corticosteroid therapy in severe illness. N Engl J Med 1997;337:1285-92.
  19. Walker BR, Williams BC. Corticosteroids and the vascular tone: mapping the messenger maze. Clin Sci 1992;82:597-605.
  20. Hollenberg SM, Cunnion RE. Endothelial and vascular smooth muscle function in sepsis. J Crit Care 1994;9:262-80.
  21. Spangelo BL, Gorospe WC. Role of cytokines in the neuroendocrine-immune system axis. Front Neuroendocrinol 1995;16:1-22.
  22. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351-62.
  23. Reichlin S. Neuroendocrine-immune interactions. N Engl J Med 1993;329:1246-53.
  24. Imura H, Fukata J. Endocrine-paracrine interaction in communication between the immune and endocrine systems: activation of the hypothalamic pituitary-adrenal axis in inflammation. Eur J Endocrinol 1994;130:32-7.
  25. Hermus AR, Sweep CG. Cytokines and the hypothalamic-pituitary-adrenal axis. J Steroid Biochem Mol Biol 1990;37:867-71.
  26. Munck A, Guyre PM, Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 1984;5:25-44.
  27. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor k B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 1998;24:1131-8.
  28. Bohrer H, Qui F, Zimmernann T, et al. Role of NF-kB in the mortality of sepsis. J Clin Invest 1997;100:972-85.
  29. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticosteroids: inhibition of NF-kB activity through induction of IkB synthesis. Science 1995;270:286-90.
  30. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr. Characterization of mechanisms involved in transrepression of NF-k B by activated glucocorticoid receptors. Mol Cell Biol 1995;15:943-53.
  31. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of the transcription factor NF-kB and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994;91:752-6.
  32. McKay LI, Cidlowski JA. Cross-talk between nuclear factor k-B and the steroid hormone receptors: mechanisms of mutual antagonism. Mol Endocrinol 1998;12:45-56.
  33. Auphan N, Didonato JA, Helmberg A, Rosette C, Karin M. Immunoregulatory genes and immunosuppression by glucocorticoids. Arch Toxicol Suppl 1997;19:87-95.
  34. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I k B a in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-6.
  35. Barnes PJ, Greening AP, Crompton GK. Glucocorticoid resistance in asthma. Am J Respir Crit Care Med 1995;152:S125-42.
  36. Detera-Wadleigh SD, Karl M. The glucocorticoid receptor gene. Ann Intern Med 1993;119:1113-24.
  37. Damas P, Ledoux D, Nys M, et al. Cytokine serum levels during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1192;215:356-62.
  38. Calandra T, Gerain J, Heumann D, et al. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 1191;91:23-9.
  39. Pinski MR, Vincent JL, Deviere J, et al. Serum cytokine levels in human septic shock: relation to multiple-organ failure and mortality. Chest 1993;103:265-75.
  40. Riche FC, Cholley BP, Panis YH, et al. Inflammatory response in patients with septic shock secondary to generalized peritonitis. Crit Care Med 2000;28:433-7.
  41. Casey LC, Balk RS, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-8.
  42. Antonelli M, Raponi GM, Martino P, et al. High IL-6 serum levels are associated with septic shock and mortality in septic shock patients with severe leukopenia due to hematological malignancies. Scand J Infect Dis 1995;27:381-4.
  43. Arnalich F, Lopez J, Codoceo R, Jimnez M, Madero R, Montiel C. Relationship of plasma leptin to plasma cytokines and human survival in sepsis and septic shock. J Infect Dis 1999;180:908-11.
  44. Arnalich F, Garcia-Palomero E, Lopez J, et al. Predictive value of nuclear factor kB activity and plasma cytokine levels in patients with sepsis. Infect Immun 2000;68:1942-5.
  45. Dofferhoff AS, Bom VJ, de Vries-Hospers HG, et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992;20:185-92.
  46. Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL. Patterns of cytokine evolution (tumor necrosis factor-a and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 1997;25:1813-19.
  47. Presterl E, Staudinger T, Pettermann M, et al. Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. Am J Respir Crit Care Med 1997;156:825-32.
  48. Meduri GU, Headley S, Kohler G, et al. Persistent elevation of inflammatory cytokines predicts poor outcome in ARDS: plasma IL-1b and IL-6 are consistent and efficient markers of outcome over time. Chest 1995;107:1062-73.
  49. Goodman RB, Strieter RM, Martin DP, et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;154:602-11.
  50. Steinberg KP, Milberg JA, Martin TR, Maunder RJ, Cockrill BA, Hudson LD. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med 1994;150:113-22.
  51. Baughman RP, Gunther KL, Rashkin MC, Keeton DA, Pattishall EN. Changes in the inflammatory response of the lung during acute respiratory distress syndrome: prognostic indicators. Am J Respir Crit Care Med 1996;154:76-81.
  52. Kiehl MG, Ostermann H, Thomas M, Muller C, Cassens U, Kienast J. Inflammatory mediators in the bronchoalveolar lavage fluid and plasma in leukopenic patients with septic shock-induced acute respiratory distress syndrome. Crit Care Med 1998;26:1194-9.
  53. Roumen RM, Hendriks T, van der Ven-Jongekrijk J, et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma: relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993;218:769-76.
  54. Hatherill M, Tibby SM, Turner C, Ratnavel N, Murdoch IA. Procalcitonin and cytokine levels: relationship to organ failure and mortality in pediatric septic shock. Crit Care Med 2000;28:2591-4.
  55. Park WY, Goodman RB, Steinberg KP, et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;164:1896-903.
  56. Donnelly SC, Strieter RM, Reid PT, et al. The association between mortality rates and the decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with adult respiratory distress syndrome. Ann Intern Med 1996;125:191-6.
  57. Shenker Y, Skatrud JB. Adrenal insufficiency in critically ill patients. Am J Respir Crit Care Med 2001;163:1520-3.
  58. Ligtenberg JJM, Girbes ARJ, Beentjes JAM, Tulleken JE, van der Werf TS, Zijlstra JG. Hormones in the critically ill patient: to intervene or not to intervene. Intensive Care Med 2001;27:1567-77.
  59. Span LF, Hermus AR, Bartelink AK, et al. Adrenocortical function: an indicator of severity of disease and survival in chronic critically ill patients. Intensive Care Med 1992;18:93-6.
  60. Vermes I, Beishuizen A, Hampsink RM, Haanen C. Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone. J Clin Endocrinol Metab 1995;80:1238-42.
  61. Schroeder S, Wishers M, Klingmuller D, et al. The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 2001;29:310-16.
  62. Ananne D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283:1038-45.
  63. Soni A, Pepper GM, Wyrwinski PM, et al. Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels. Am J Med 1995;98:266-71.
  64. Aygen B, Inan M, Doganay M, Kelestimur F. Adrenal function in patients with sepsis. Exp Clin Endocrinol Diabetes 1997;105:182-6.
  65. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991;337:582-3.
  66. Jurney TH, Cockrell JL Jr, Lindberg JS, Lamiell JM, Wade CE. Spectrum of serum cortisol response to ACTH in ICU patients: correlation with degree of illness and mortality. Chest 1987;92:292-5.
  67. Jarek MJ, Legare EJ, McDermott MT, Merenich JA, Kollef MH. Endocrine profiles for outcome prediction from the intensive care unit. Crit Care Med 1993;21:543-50.
  68. Drucker D, McLaughlin J. Adrenocortical dysfunction in acute medical illness. Crit Care Med 1986;14:789-91.
  69. Sibbald WJ, Short A, Cohen MP, Wilson RF. Variations in adrenocortical responsiveness during severe bacterial infections: unrecognized adrenocortical insufficiency in severe bacterial infections. Ann Surg 1977;186:29-33.
  70. Schein RM, Sprung CL, Marcial E, Napolitano L, Chernow B. Plasma cortisol levels in patients with septic shock. Crit Care Med 1990;18:259-63.
  71. Bouachour G, Tirot P, Gouello JP, Mathieu E, Vincent JF, Alquier P. Adrenocortical function during septic shock. Intensive Care Med 1995;21:57-62.
  72. Finlay WEI, McKee JI. Serum cortisol levels in severely stressed patients [letter]. Lancet 1982;1:1414-15.
  73. McKee JI, Finlay WEI. Cortisol replacement in severely stressed patients [letter]. Lancet 1983;1:484.
  74. Briegel J, Schelling G, Haller M, Mraz W, Forst H, Peter K. A comparison of the adrenocortical response during septic shock and after complete recovery. Intensive Care Med 1996;22:894-9.
  75. Vadas P, Pruzanski W, Stefanski E, et al. Concordance of endogenous cortisol and phospholipase A2 levels in gram-negative septic shock: a prospective study. J Lab Clin Med 1988;111:584-90.
  76. Rothwell PM, Lawler PG. Prediction of outcome in intensive care patients using endocrine parameters. Crit Care Med 1995;23:78-83.
  77. Moran JL, Chapman MJ, O'Fathartaigh MS, Peisach AR, Pannall PR, Leppard P. Hypocortisolaemia and adrenocortical responsiveness at onset of septic shock. Intensive Care Med 1994;20:489-95.
  78. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome. Am J Respir Crit Care Med 2002;165:983-91.
  79. Meduri GU. Duration of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way? Chest 1998;114:355-9.
  80. Gaillard RC, Turnill D, Sappino P, Muller AF. Tumor necrosis factor a inhibits the hormonal response to the pituitary gland to hypothalamic releasing factors. Endocrinology 1990;127:101-6.
  81. Reincke M, Allolio B, Wurth G, Winkelmann W. The hypothalamic-pituitary-adrenal axis in critical illness: response to dexamethasone and corticotropin-releasing hormone. J Clin Endocrinol Metab 1993;77:151-6.
  82. Hammond GL. Potential functions of plasma steroid-binding proteins. Trends Endocrinol Metab 1995;152:S125-42.
  83. Beishuizen A, Thijs LG, Vermes I. Patterns of corticosteroid-binding globulin and free cortisol index during septic shock and multitrauma. Intensive Care Med 2001;27:1584-91.
  84. Pugeat M, Bonneton A, Perrot D, et al. Decreased immuno-reactivity and binding activity of corticosteroid-binding globulin in serum in septic shock. Clin Chem 1989;35: 1675-9.
  85. Savu L, Zouaghi H, Carli A, Nunez EA. Serum depletion of corticosteroid binding activities: an early marker of human septic shock. Biochem Biophysical Res Comm 1981;102:411-19.
  86. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of dominant negative b isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci USA 2001;98:6865-70.
  87. Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB. Abrogation of glucocorticosteroid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-g. J Immunol 1991;146:3523-7.
  88. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DYM. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 1993;151:3460-6.
  89. Perla D, Marmorston J. Suprarenal cortisol hormone and salt in the treatment of pneumonia and other severe infections. Endocrinology 1940;27:367-74.
  90. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23:1294-303.
  91. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23:1430-9.
  92. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976;184:333-41.
  93. Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock: a prospective, controlled study. N Engl J Med 1984;311:1137-43.
  94. Clemmer TP, Fisher CJ Jr, Bone RC, Slotman GJ, Metz CA, Thomas FO. Hypothermia in the sepsis syndrome and clinical outcome: the methylprednisolone severe sepsis study group. Crit Care Med 1992;20:1395-401.
  95. Lucas CE, Ledgerwood AM. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg 1984;119:537-41.
  96. Briegel J, Jochum M, Gippner-Steppert C, Thiel M. Immunomodulation in septic shock: hydrocortisone differentially regulates cytokine responses. J Am Soc Nephrol 2001;12:S70-4.
  97. Briegel J, Kellermann W, Forst H, et al. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. Clin Investig 1994;72:782-7.
  98. Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998;46:589-97.
  99. Saito T, Takanashi M, Gallagher E, et al. Corticosteroid effect on early b-adrenergic down-regulation during circulatory shock: hemodynamic study and b-adrenergic receptor assay. Intensive Care Med 1995;21:204-10.
  100. Bellissant E, Annane D. Effect of hydrocortisone on phenylephrine: mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther 2000;68:293-303.
  101. Van Leeuwen HJ, van der Bruggen T, van Asbeck BS, Boereboom FT. Effect of corticosteroids on nuclear factor kB activation and hemodynamics in late septic shock. Crit Care Med 2001;29:1074-7.
  102. Duggan M, Browne I, Flynn C. Adrenal failure in the critically ill. Br J Anaesth 1998;81:468-70.
  103. Schneider AJ, Voerman HJ. Abrupt hemodynamic improvement in late septic shock with physiological doses of glucocorticoids [letter]. Intensive Care Med. 1991;17:436-7.
  104. Benfield K, Cooper J, Scheinkestel CD, Tuxen DV. Relative adrenal insufficiency in patients with septic shock [abstr]. Anaesth Intensive Care 1994;22:215-16.
  105. Briegel J, Forst H, Hellinger H, Haller M. Contribution of cortisol deficiency to septic shock [letter]. Lancet 1991;338:507-8.
  106. Spijkstra JJ, Schreuder WO. Beneficial effects of corticosteroids in septic shock [abstr]. Intensive Care Med 1995;21:S15.
  107. Knighton JD, Woodock TE, Hough M. Adrenal failure in the critically ill [letter]. Br J Anaesth 1999;82:152-3.
  108. Oppert M, Reinicke A, Graf KJ, Barckow D, Frei U, Eckart KU. Plasma cortisol levels before and during "low-dose" hydrocortisone therapy and their relationship to hemodynamic improvement in patients with septic shock. Intensive Care Med 2000;26:1747-55.
  109. Cooperative Study Group. The effectiveness of hydro-cortisone in the management of severe infections. JAMA 1963;183:462-5.
  110. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999;27:723-32.
  111. Chawla K, Kupfer Y, Goldman I, Tessler S. Hydrocortisone reverses refractory septic shock [abstr]. Crit Care Med 1999;27:A33.
  112. Hoffman SL, Punjabi NH, Kumala S, et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med 1984;310:82-8.
  113. Annane D. Effects of the combination of hydrocortisone (HC)-fludro-cortisone (FC) on mortality in septic shock [abstr]. Crit Care Med 2000;28:A46.
  114. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645-50.
  115. Schelling G, Stoll C, Kapfhammer HP, et al. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder and health-related quality of life in survivors. Crit Care Med 1999;27:2678-83.
  116. Meduri GU, Headley S, Tolley E, Shelby M, Stentz F, Postlethwaite A. Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. 1995;108: 1315-25.
  117. Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 1998;158:1432-41.
  118. Braude S, Haslam P, Hughes D, Macnaughton P, Evans TW. Chronic adult respiratory distress syndrome: a role for corticosteroids? Crit Care Med 1992;20:1187-9.
  119. Hooper RG, Kearl RA. Established adult respiratory distress syndrome successfully treated with corticosteroids. Chest 1990;97:138-43.
  120. Ashbaugh DG, Maier RV. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome. Arch Surg 1985;120: 530-5.
  121. Biffl WL, Moore FA, Moore EE, Haenel JB, McIntyre RC, Burch JM. Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome? Am J Surg 1995;170:591-6.
  122. Meduri GU, Chinn AJ, Leeper KV, et al. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS: patterns of response and predictors of outcome. Chest 1994;105:1516-27.
  123. Varpula T, Pettila V, Rintala E, Takkunen O, Valtonen V. Late steroid therapy in primary acute lung injury. Intensive Care Med 2000;26:526-31.
  124. Keel JBP, Hauser M, Stocker R, Baumann PC, Speich R. Established acute respiratory distress syndrome: benefit of corticosteroid rescue therapy. Respiration 1998;65:258-64.
  125. Mer M, Richards GA. Corticosteroids in life-threatening varicella pneumonia. Chest 1998;114:426-31.
  126. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. JAMA 1998;280:159-65.
  127. ARDS Net. Late steroid rescue study. Available from Accessed June 3, 2002.
  128. Barber AE, Coyle SM, Marano MA, et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993;150:1999-2006.
  129. Kim JK, Summer SN, Wood WM, Schrier RW. Role of glucocorticoid hormones in arginine vasopressin gene regulation. Biochem Biophys Res Commun 2001;289:1252-6.
  130. Bernard GR, Vincent JL, Laterre PE, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.